Mithrl Raises $20M for Biopharma AI
Mithrl has raised a $20 million Series A to build AI infrastructure that connects biomedical models with proprietary pharma data and research workflows.
Biopharma companies do not just need access to powerful models; they need those models to understand proprietary experiments, internal datasets and validated scientific context. Mithrl has raised $20 million to build that integration layer.
What happened
The Series A was led by Obvious Ventures, with participation from Headline, AGI House and executives from the pharmaceutical industry.
Mithrl's platform combines a proprietary biomedical world model with model routing, context orchestration and AI agents. The system is designed to operate inside biopharma companies' own environments rather than forcing sensitive research data into a generic external workflow.
Why it matters
General-purpose AI can summarise papers or generate hypotheses, but drug research depends on domain-specific evidence and internal data that may never appear in public training sets.
Connecting models to that information while preserving permissions, provenance and scientific context is becoming a key infrastructure problem for pharma.
The bigger picture
AI drug discovery is broadening from companies that directly design molecules into companies building operating systems for scientific work.
Mithrl represents that second layer: infrastructure that lets pharmaceutical teams combine multiple models with proprietary knowledge. If biopharma AI matures, the value may increasingly sit in these orchestration and data layers rather than in a single foundation model.